GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (FRA:2LB) » Definitions » 50-Day SMA

Iovance Biotherapeutics (FRA:2LB) 50-Day SMA : €11.26 (As of Jun. 01, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Iovance Biotherapeutics 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-06-01), Iovance Biotherapeutics's 50-Day SMA is €11.26. It's 20-Day SMA is €10.16 and 200-Day SMA is €8.06.


Competitive Comparison of Iovance Biotherapeutics's 50-Day SMA

For the Biotechnology subindustry, Iovance Biotherapeutics's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iovance Biotherapeutics's 50-Day SMA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's 50-Day SMA falls into.



Iovance Biotherapeutics  (FRA:2LB) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Iovance Biotherapeutics  (FRA:2LB) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Iovance Biotherapeutics 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Iovance Biotherapeutics (FRA:2LB) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics (FRA:2LB) Headlines

No Headlines